|
Gene: GFPT2 |
Gene summary for GFPT2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GFPT2 | Gene ID | 9945 |
Gene name | glutamine-fructose-6-phosphate transaminase 2 | |
Gene Alias | GFAT | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0006002 | UniProtAcc | A0A0S2Z4X9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9945 | GFPT2 | P5T-E | Human | Esophagus | ESCC | 6.26e-18 | 3.65e-01 | 0.1327 |
9945 | GFPT2 | P11T-E | Human | Esophagus | ESCC | 1.21e-05 | 2.17e-01 | 0.1426 |
9945 | GFPT2 | P22T-E | Human | Esophagus | ESCC | 4.54e-02 | 3.08e-02 | 0.1236 |
9945 | GFPT2 | P24T-E | Human | Esophagus | ESCC | 2.84e-04 | 2.10e-01 | 0.1287 |
9945 | GFPT2 | P28T-E | Human | Esophagus | ESCC | 8.30e-06 | 1.23e-01 | 0.1149 |
9945 | GFPT2 | P31T-E | Human | Esophagus | ESCC | 1.46e-07 | 8.83e-02 | 0.1251 |
9945 | GFPT2 | P32T-E | Human | Esophagus | ESCC | 6.75e-05 | 1.70e-01 | 0.1666 |
9945 | GFPT2 | P37T-E | Human | Esophagus | ESCC | 3.57e-07 | 1.11e-01 | 0.1371 |
9945 | GFPT2 | P42T-E | Human | Esophagus | ESCC | 2.08e-04 | 1.31e-01 | 0.1175 |
9945 | GFPT2 | P44T-E | Human | Esophagus | ESCC | 7.13e-04 | 2.80e-01 | 0.1096 |
9945 | GFPT2 | P52T-E | Human | Esophagus | ESCC | 5.65e-17 | 5.11e-01 | 0.1555 |
9945 | GFPT2 | P54T-E | Human | Esophagus | ESCC | 3.45e-05 | 6.70e-02 | 0.0975 |
9945 | GFPT2 | P61T-E | Human | Esophagus | ESCC | 3.73e-05 | 2.07e-01 | 0.099 |
9945 | GFPT2 | P62T-E | Human | Esophagus | ESCC | 4.65e-02 | 1.06e-01 | 0.1302 |
9945 | GFPT2 | P74T-E | Human | Esophagus | ESCC | 2.28e-06 | 6.64e-02 | 0.1479 |
9945 | GFPT2 | P76T-E | Human | Esophagus | ESCC | 1.89e-02 | 5.08e-02 | 0.1207 |
9945 | GFPT2 | P80T-E | Human | Esophagus | ESCC | 3.04e-04 | 4.97e-01 | 0.155 |
9945 | GFPT2 | P83T-E | Human | Esophagus | ESCC | 3.14e-04 | 1.89e-01 | 0.1738 |
9945 | GFPT2 | P89T-E | Human | Esophagus | ESCC | 4.44e-02 | 4.40e-01 | 0.1752 |
9945 | GFPT2 | P107T-E | Human | Esophagus | ESCC | 2.31e-02 | 7.70e-02 | 0.171 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
GO:0015980110 | Esophagus | ESCC | energy derivation by oxidation of organic compounds | 220/8552 | 318/18723 | 1.20e-17 | 1.09e-15 | 220 |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00092256 | Esophagus | ESCC | nucleotide-sugar metabolic process | 29/8552 | 36/18723 | 1.91e-05 | 1.67e-04 | 29 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:199082316 | Esophagus | ESCC | response to leukemia inhibitory factor | 60/8552 | 95/18723 | 4.41e-04 | 2.48e-03 | 60 |
GO:199083015 | Esophagus | ESCC | cellular response to leukemia inhibitory factor | 59/8552 | 94/18723 | 6.19e-04 | 3.32e-03 | 59 |
GO:00092262 | Esophagus | ESCC | nucleotide-sugar biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
GO:001598034 | Thyroid | ATC | energy derivation by oxidation of organic compounds | 177/6293 | 318/18723 | 3.60e-16 | 2.92e-14 | 177 |
GO:000648715 | Thyroid | ATC | protein N-linked glycosylation | 38/6293 | 65/18723 | 3.39e-05 | 2.80e-04 | 38 |
GO:000922511 | Thyroid | ATC | nucleotide-sugar metabolic process | 24/6293 | 36/18723 | 5.10e-05 | 3.99e-04 | 24 |
GO:00060471 | Thyroid | ATC | UDP-N-acetylglucosamine metabolic process | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:199082318 | Thyroid | ATC | response to leukemia inhibitory factor | 44/6293 | 95/18723 | 6.74e-03 | 2.68e-02 | 44 |
GO:000648612 | Thyroid | ATC | protein glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
GO:004341312 | Thyroid | ATC | macromolecule glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GFPT2 | SNV | Missense_Mutation | rs752268045 | c.487N>A | p.Glu163Lys | p.E163K | O94808 | protein_coding | tolerated(0.59) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GFPT2 | SNV | Missense_Mutation | c.1442N>A | p.Ser481Asn | p.S481N | O94808 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
GFPT2 | SNV | Missense_Mutation | novel | c.1709N>A | p.Gly570Asp | p.G570D | O94808 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
GFPT2 | SNV | Missense_Mutation | c.1006T>G | p.Ser336Ala | p.S336A | O94808 | protein_coding | deleterious(0.02) | possibly_damaging(0.76) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
GFPT2 | SNV | Missense_Mutation | rs757899837 | c.127N>A | p.Asp43Asn | p.D43N | O94808 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
GFPT2 | SNV | Missense_Mutation | c.838G>A | p.Asp280Asn | p.D280N | O94808 | protein_coding | tolerated(0.26) | benign(0.075) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR | |
GFPT2 | SNV | Missense_Mutation | rs767726394 | c.1417G>T | p.Val473Leu | p.V473L | O94808 | protein_coding | deleterious(0) | benign(0.43) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GFPT2 | SNV | Missense_Mutation | c.421G>A | p.Glu141Lys | p.E141K | O94808 | protein_coding | tolerated(0.09) | probably_damaging(0.981) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
GFPT2 | insertion | Nonsense_Mutation | novel | c.1169_1170insCTCCTGCCATTTTCCATTTTAAATACCATTTCC | p.Glu390delinsAspSerCysHisPheProPheTerIleProPhePro | p.E390delinsDSCHFPF*IPFP | O94808 | protein_coding | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
GFPT2 | insertion | Frame_Shift_Ins | novel | c.1851dupC | p.Ile618HisfsTer10 | p.I618Hfs*10 | O94808 | protein_coding | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |